- Home
- PBYI vs BDTX Comparison
PBYI vs BDTX Comparison
Compare PBYI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- BDTX
- Stock Information
- Founded
- PBYI 2010
- BDTX 2014
- Country
- PBYI United States
- BDTX United States
- Employees
- PBYI N/A
- BDTX N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PBYI Health Care
- BDTX Health Care
- Exchange
- PBYI Nasdaq
- BDTX Nasdaq
- Market Cap
- PBYI 171.7M
- BDTX 181.4M
- IPO Year
- PBYI N/A
- BDTX 2020
- Fundamental
- Price
- PBYI $5.73
- BDTX $2.76
- Analyst Decision
- PBYI Strong Buy
- BDTX Strong Buy
- Analyst Count
- PBYI 1
- BDTX 5
- Target Price
- PBYI $7.00
- BDTX $13.40
- AVG Volume (30 Days)
- PBYI 736.1K
- BDTX 914.3K
- Earning Date
- PBYI 08-07-2025
- BDTX 08-07-2025
- Dividend Yield
- PBYI N/A
- BDTX N/A
- EPS Growth
- PBYI 434.29
- BDTX N/A
- EPS
- PBYI 0.97
- BDTX 0.25
- Revenue
- PBYI $238,062,000.00
- BDTX $70,000,000.00
- Revenue This Year
- PBYI N/A
- BDTX N/A
- Revenue Next Year
- PBYI N/A
- BDTX N/A
- P/E Ratio
- PBYI $5.89
- BDTX $11.03
- Revenue Growth
- PBYI 8.63
- BDTX N/A
- 52 Week Low
- PBYI $2.23
- BDTX $1.20
- 52 Week High
- PBYI $5.81
- BDTX $6.75
- Technical
- Relative Strength Index (RSI)
- PBYI 88.88
- BDTX 52.31
- Support Level
- PBYI $3.05
- BDTX $2.22
- Resistance Level
- PBYI $5.06
- BDTX $2.84
- Average True Range (ATR)
- PBYI 0.35
- BDTX 0.20
- MACD
- PBYI 0.27
- BDTX -0.01
- Stochastic Oscillator
- PBYI 97.16
- BDTX 72.00
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.